Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
14 May 2024
04:55 | Somatrogon-ghla diffhist +52 Kosar Doraghi talk contribs |
13 May 2024
N 23:48 | Fezolinetant diffhist +84 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=fezolinetant }}") |
|
N 23:46 | Nirsevimab-alip 2 changes history +5,780 [Alen Antony (2×)] | |||
|
23:46 (cur | prev) +3,844 Alen Antony talk contribs | ||||
N |
|
14:50 (cur | prev) +1,936 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Nirsevimab-alip |aOrAn=a |drugClass=human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody |indicationType=prevention |indication=Respiratory Syncytial Virus (RSV) lower respiratory tract disease for neonates and infants born during or entering their first RSV season and children up to 24 years of age who are vulnerable to severe RSV disease in their second RSV season. |adverseReactions=rashes and injection...") |
|
m 22:04 | Non-degenerate nucleotides per response element 3 changes history −233 [Marshallsumter (3×)] | |||
m |
|
22:04 (cur | prev) −60 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
08:12 (cur | prev) −2 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
07:26 (cur | prev) −171 Marshallsumter talk contribs (→Tabulation of counts) |
N 20:38 | Talquetamab-tgvs diffhist +2,766 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Talquetamab-tgvs |aOrAn=a |drugClass=bispecific GPRC5D-directed CD3 T-cell engager |indicationType=treatment |indication=TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent...") |
14:23 | Non-alcoholic fatty liver disease epidemiology and demographics diffhist +1,197 Badgettrg talk contribs (→Overview) |
12 May 2024
|
m 23:34 | Non-degenerate nucleotides per response element 3 changes history −150 [Marshallsumter (3×)] | |||
m |
|
23:34 (cur | prev) −149 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
22:44 (cur | prev) −49 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
22:34 (cur | prev) +48 Marshallsumter talk contribs (→Tabulation of counts) |
|
23:08 | Vitamin D 2 changes history +1,636 [Badgettrg (2×)] | |||
|
23:08 (cur | prev) +503 Badgettrg talk contribs (→Medical uses) | ||||
|
23:00 (cur | prev) +1,133 Badgettrg talk contribs (→Role in depression prevention) |
21:59 | Systematic review diffhist +3,699 Badgettrg talk contribs (→Living systematic reviews) |
21:06 | Template:KDRG diffhist +47 Kosar Doraghi talk contribs |
|
N 21:04 | Somatrogon-ghla 2 changes history +12,691 [Kosar Doraghi (2×)] | |||
|
21:04 (cur | prev) +215 Kosar Doraghi talk contribs | ||||
N |
|
05:30 (cur | prev) +12,476 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.con] |genericName=somatrogon-ghla |aOrAn=a |drugClass=human growth hormone analog |indicationType=treatment |indication=pediatric patients aged 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone |hasBlackBoxWarning=Yes |adverseReactions=injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, v...") |
20:52 | Chronic renal failure overview diffhist +13,854 Kosar Doraghi talk contribs |
|
19:35 | (Upload log) [Kosar Doraghi (8×)] | |||
|
19:35 Kosar Doraghi talk contribs uploaded File:IMG 1208.jpeg | ||||
|
19:33 Kosar Doraghi talk contribs uploaded File:IMG 1207.jpeg | ||||
|
19:32 Kosar Doraghi talk contribs uploaded File:IMG 1204.jpeg | ||||
|
19:30 Kosar Doraghi talk contribs uploaded File:IMG 1202.jpeg | ||||
|
19:28 Kosar Doraghi talk contribs uploaded File:IMG 1200.jpeg | ||||
|
19:24 Kosar Doraghi talk contribs uploaded File:IMG 1214.jpeg | ||||
|
05:15 Kosar Doraghi talk contribs uploaded File:IMG 1198.jpeg | ||||
|
05:13 Kosar Doraghi talk contribs uploaded File:IMG 1215.jpeg |
11 May 2024
|
22:32 | Mirikizumab-mrkz 3 changes history +5,248 [Rithish Nimmagadda (3×)] | |||
|
22:32 (cur | prev) +13 Rithish Nimmagadda talk contribs | ||||
|
22:31 (cur | prev) 0 Rithish Nimmagadda talk contribs | ||||
|
22:26 (cur | prev) +5,235 Rithish Nimmagadda talk contribs |
N 20:21 | Elfabrio diffhist +3,351 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=Pegunigalsidase Alfa-iwxj |drugClass=a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme, is a pegylated recombinant form of human α-galactosidase A |indicationType=treatment |indication=ELFABRIO is an FDA approved drug that is used for treatment of adults with confirmed Fabry disease. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (≥15%) are infusion-associated reactio...") |
N 19:36 | Exxua diffhist +44 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{ }}") |
|
19:09 | Facioscapulo-humeral dystrophy 8 changes history +2,898 [Dj (8×)] | |||
|
19:09 (cur | prev) +29 Dj talk contribs (→History) | ||||
|
18:59 (cur | prev) +191 Dj talk contribs | ||||
|
18:45 (cur | prev) +637 Dj talk contribs (→Pathophysiology) | ||||
|
18:41 (cur | prev) +138 Dj talk contribs | ||||
|
17:59 (cur | prev) +789 Dj talk contribs (→Classification) | ||||
|
17:52 (cur | prev) −5 Dj talk contribs | ||||
|
17:51 (cur | prev) +363 Dj talk contribs | ||||
|
17:43 (cur | prev) +756 Dj talk contribs |
12:13 | User:Archana.vajjala diffhist +62 Archana.vajjala talk contribs (→Interests) |